Skip to main content

Biodesix's GeneStrat Includes ROS1 and RET Mutations

Biodesix has broadened its GeneStrat liquid biopsy test to include ROS1 and RET mutations in addition to EGFR sensitizing, EGFR resistance, KRAS, BRAF, and EML4-ALK alterations.

GeneStrat is a part of the Biodesix's larger "Lung Reflex" multi-omic liquid biopsy testing strategy, which also includes the VeriStrat proteomic testing. With results available within 72 hours, the company says that GeneStrat and VeriStrat together deliver comprehensive information for physicians to support critical treatment decisions at initial diagnosis, expediting appropriate treatment.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.